BRISBANE & MELBOURNE, 28 November, 2019

Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will present today at the Pitt Street Research Life Sciences Conference, held in Sydney, NSW.

Steve will discuss the Company's recently announced preclinical data and why it provides Anatara with every confidence going into a human clinical study next year. In parallel, Steve will provide an update on the Company's plans to build a pipeline of human gastrointestinal (GI) health products. Anatara is currently evaluating a range of evidence-based GI health consumer products, already commercialised in international markets, with negotiations underway with one potential product partner.

Anatara’s CEO, Mr. Steven Lydeamore said, “We are coming into an exciting news flow period for the Company and we now have the opportunity to expand our gastrointestinal health footprint in the consumer health market in Australia. For those reasons, I am very optimistic about our future and look forward to delivering value and growth for shareholders.”

Please click here to view the ASX announcement.